TABLE 1.
Patient characteristics
| Nonmetastatic cancer (n = 43) | Metastatic cancer (n = 7) | |
|---|---|---|
| Age (years) [median (range)] | 76 (58–88) | 73 (62–80) |
| Gender, n (%) | ||
| Male | 36 (84) | 7 (100) |
| Female | 7 (16) | 0 (0) |
| BMI (kg/m2) [median (range)] | 22.9 (16.8–33.5) | 21.6 (18.4–27.4) |
| Smoking history, n (%) | ||
| Yes | 33 (77) | 5 (71) |
| No | 10 (23) | 2 (29) |
| Tumor location, n (%) | ||
| Renal pelvis | 17 (40) | 6 (86) |
| Ureter | 25 (58) | 0 (0) |
| Both | 1 (2) | 1 (14) |
| Urine cytology, n (%) | ||
| 1–3 | 24 (56) | 3 (43) |
| 4–5 | 19 (44) | 4 (57) |
| Hydronephrosis, n (%) | ||
| Yes | 18 (42) | 5 (71) |
| No | 25 (58) | 2 (29) |
| UBC history, n (%) | ||
| Former | 12 (28) | 2 (29) |
| Never | 31 (72) | 5 (71) |
| NLR [median (range)] | 2.6 (1.3–9.4) | 6.9 (2.6–14.0) |
| Clinical T stage, n (%) | ||
| cTa,is,1 | 14 (33) | 0 (0) |
| cT2 | 22 (51) | 2 (29) |
| cT3 | 7 (16) | 2 (29) |
| cT4 | 0 (0) | 3 (42) |
| Clinical N stage, n (%) | ||
| cN0 | 42 (98) | 1 (14) |
| cN1 | 1 (2) | 2 (29) |
| cN2 | 0 (0) | 4 (57) |
| Clinical M stage, n (%) | ||
| cM0 | 43 (100) | 3 (43) |
| cM1 | 0 (0) | 4 (57) |
| Pathological T stage, n (%) | ||
| pTa,is,1 | 18 (42) | |
| pT2 | 7 (16) | |
| pT3 | 17 (40) | |
| pT4 | 1 (2) | |
| Pathological N stage, n (%) | ||
| pN0 | 29 (67) | |
| pN1 | 5 (12) | |
| pN2 | 2 (5) | |
| pNx | 7 (16) | |
| CIS, n (%) | ||
| Negative | 38 (88) | |
| Positive | 5 (12) | |
| Lymphovascular invasion, n (%) | ||
| Negative | 23 (53) | |
| Positive | 20 (47) | |
| Adjuvant chemotherapy, n (%) | ||
| Yes | 11 (26) | |
| No | 32 (74) | |
Abbreviations: CIS, concomitant carcinoma in situ; NLR, neutrophil‐to‐lymphocyte ratio; UBC, urothelial bladder cancer.